BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Warns Celltex Therapeutics Corporation Over Violations


10/17/2012 7:50:41 AM

Last April, the FDA inspected Celltex Therapeutics, which has ties to a controversial stem cell company in South Korea called RNL BIO, after a University of Minnesota bioethics professor wrote the agency to over concerns about patient safety, quality of scientific research supporting the proposed business model and whether both conform to federal and state laws and regulations. At the time, the agency issued a 483 inspection listing dozens of violations (see here). Now, the FDA has sent a warning letter, citing Celltex for developing a product that is an unlicensed biologic and for violating numerous good manufacturing practices, including a failure to establish and follow written procedures designed to prevent microbiological contamination. The list of problems is, in fact, quite long and also mentions a failure to validate cell culture processes and conduct sterility investigations, as well as a failure to create a quality-control unit to approve or reject components and containers, among other things. There was also a failure to establish a written record of major equipment cleaning, maintenance and use.

Read at Pharmalot
Read at News Release
Read at FDA

Pharmalot
News Release
FDA
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES